Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29445869 | 1.00 | HTR1A (0.36) | HTR1ADRD2CA12BRD4BRPF1 | |
| SCHEMBL4999235 | 0.81 | HTR1A (0.38) | HTR1ADRD2CA12BRD4BRPF1 | |
| SCHEMBL4360956 | 0.73 | HTR1A (0.39) | HTR1A | |
| SCHEMBL30832178 | 0.72 | MCL1 (0.52) | — | |
| SCHEMBL9272471 | 0.69 | — | — | |
| SCHEMBL1650468 | 0.69 | HTR1A (0.43) | HTR1ADRD2 | |
| SCHEMBL3125224 | 0.68 | PARP1 (0.37) | HTR1A | |
| SCHEMBL25193535 | 0.67 | KDM4E (0.31) | — | |
| SCHEMBL6173719 | 0.67 | HDAC6 (0.32) | HTR1ADRD2 | |
| SCHEMBL8905089 | 0.67 | KDM4E (0.38) | HTR1ADRD2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114306604-A | Use of farnesyl transferase inhibitors for the treatment of cancer | 库拉肿瘤学公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-110325212-B | Farnesyl transferase inhibitors for use in methods of treating cancer | 库拉肿瘤学公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114107497-A | Use of farnesyl transferase inhibitors for the treatment of cancer | 库拉肿瘤学公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-111214658-B | Methods of treating cancer patients with farnesyl transferase inhibitors | 库拉肿瘤学公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-107787373-B | Use of farnesyl transferase inhibitors for the treatment of cancer | 库拉肿瘤学公司 | 2021-11-26 | — | — | CN | disclosed |
| US-11124839-B2 | Methods of treating cancer patients with farnesyltransferase inhibitors | KURA ONCOLOGY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| WO-2020190604-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| CN-111214658-A | Methods of treating cancer patients with farnesyl transferase inhibitors | 库拉肿瘤学公司 | 2020-06-02 | — | — | CN | disclosed |
| EP-3534885-A2 | FARNESYLTRANSFERASE INHIBITORS FOR USE IN METHODS OF TREATING CANCER | Kura Oncology, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| WO-2019113269-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20180187266-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| EP-3277842-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | Kura Oncology, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2017031101-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYL TRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | HTR1A 339/4885DRD2 837/4885CA12 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.